3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Wilms Tumor
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Medulloblastoma
1
Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
lutetium Lu 177 dotatate
5
surufatinib
4
gallium Ga 68 dotatate
4
Nivolumab
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Everolimus
3
selpercatinib
2
olaparib
2
lanreotide
2
avelumab
2
Radiotherapy
2
Paclitaxel
2
Etoposide
2
3-Iodobenzylguanidine
2
veliparib
1
vandetanib
1
tivozanib
1
tislelizumab
1
spartalizumab
1
sapanisertib
1
repotrectinib
1
regorafenib
1
pralsetinib
1
pegfilgrastim
1
irinotecan sucrosofate
1
iodophenyl metomidate
1
fosbretabulin
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
entrectinib
×
Endocrine
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA